Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 439 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers

Glycoprotein Matrix-Bound Iron Improves Iron Absorption

NCT06738199
Conditions
Evaluation of Bioavailability of Supplemental Forms of Iron
Interventions
dietary iron supplementation
Dietary Supplement
Lead sponsor
University of Mary Hardin-Baylor
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Belton, Texas
Conditions
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
Interventions
deferasirox
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Duarte, California
Conditions
Anemia
Interventions
Oral iron tablets, VIT-45
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
Female only
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Interventions
Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions
deferasirox
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed No phase listed Observational

MRI QSM Imaging for Iron Overload

NCT04631718
Conditions
Hemochromatosis, Iron Overload
Interventions
Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
5 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Stanford, California • Madison, Wisconsin
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Non-Anemic Iron Deficiency in Pregnancy

NCT05423249
Conditions
Non-anemic Iron Deficiency
Interventions
Ferrous sulfate, Prenatal, Docusate Sodium, Ascorbic Acid 500Mg Tab, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Bohemia, New York • Commack, New York • East Setauket, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Duration of Red Blood Cell Storage Prior to Transfusion

NCT02087514
Conditions
Iron, Blood Level Abnormal
Interventions
Blood Transfusion, Packed red blood cells
Procedure · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Anemia
Interventions
ferumoxytol, moxifloxacin, placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Anemia, Myelodysplastic Syndrome
Interventions
Deferasirox, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions
Iron Sucrose
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

NCT02143518
Conditions
Hookworm Infection, Hookworm Disease
Interventions
Na-GST-1/Alhydrogel®, CpG 10104
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Not applicable Interventional Results available

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

NCT01755455
Conditions
Cystic Fibrosis, Anemia, Iron-Deficiency
Interventions
Ferrous sulfate 325mg, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Portland, Maine • Lebanon, New Hampshire
Conditions
Atherosclerosis, Intermittent Claudication, Peripheral Vascular Diseases
Interventions
Ferritin reduction to 25 ng/ml by phlebotomy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
1,277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • No. Little Rock, Arkansas • Long Beach, California + 20 more
Conditions
Iron Deficiency Anemia
Interventions
Iron isomaltoside 1000, Natrium Chloride 0,9%
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Anemia
Interventions
VIT-45, Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

How Does Perimenopausal Menorrhagia Affect Women's Quality of Life and Cognitive Function?

NCT06798584
Conditions
Iron Deficiency Anemia Treatment, Iron Deficiency, Iron Deficiency (Without Anemia)
Interventions
FeoSol Original Iron Supplement Tablets, 21st Century Gelatin Capsules
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Completed Not applicable Interventional Accepts healthy volunteers

BLOODSAFE Ghana- Iron and Nutritional Counselling Strategy

NCT06101238
Conditions
Blood Donation
Interventions
supplementation with low dose elemental iron
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Neurodegeneration With Brain Iron Accumulation (NBIA)
Interventions
Not listed
Lead sponsor
Susan J. Hayflick
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Very Low Birth Weight Infant, Premature Infants, Anemia of Prematurity, Iron Deficiency, Anaemia in Children, Extremely Low Birth Weight
Interventions
6 mg/kg of oral iron as ferrous sulfate administered every other day., 6 mg/kg of oral iron as ferrous sulfate administered every day.
Dietary Supplement
Lead sponsor
CHRISTUS Health
Other
Eligibility
26 Weeks to 32 Weeks
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Recruiting Not applicable Interventional Accepts healthy volunteers

Dietary Iron Requirements

NCT07139821
Conditions
Iron Absorption
Interventions
Stable iron isotope
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Ithaca, New York
Conditions
Bladder Cancer, Genitourinary Cancer, Prostate Cancer
Interventions
Ferumoxtran-10 (USPIO), MR lymphangiography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas